James S Bus (J S Bus)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Topics

Induced Pluripotent Stem Cells

Gold Nanoparticles

Top Venues

Journal of toxicology and environmental health. Part B, Critical reviews

Exponent Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Exponent Inc

United States

Sr Managing Scientist :: Center for Toxicology and Mechanistic Biology

Dow Chemical Co

United States

Director of External Technology :: Toxicology and Environmental Research and Consulting

The Upjohn Company

United States

Associate Director (Toxicology); Director (Drug Metabolism) :: Toxicology/Drug Metabolism

Chemical Industry Institute of Toxicology (CIIT)

United States

Research Scientist

University of Cincinnati

United States

Assistant Professor (Toxicology) :: Environmental Heatlh (Toxicology)

Publications

James S Bus, B Bhaskar Gollapudi, Gordon C Hard
Methyl-tert-butyl ether (MTBE): integration of rat and mouse carcinogenicity data with mode of action and human and rodent bioassay dosimetry and toxicokinetics indicates MTBE is not a plausible human carcinogen. Journal of toxicology and environmental health. Part B, Critical reviews 25 (4) (2022)
C R Kirman, A A Li, P J Sheehan, James S Bus, R C Lewis, S M Hays
Ethylene oxide review: characterization of total exposure via endogenous and exogenous pathways and their implications to risk assessment and risk management. Journal of toxicology and environmental health. Part B, Critical reviews 24 (1) (2020)
Samuel M Cohen, Yan Zhongyu, James S Bus
Relevance of mouse lung tumors to human risk assessment. Journal of toxicology and environmental health. Part B, Critical reviews 23 (5) (2020)
M I Banton, James S Bus, J J Collins, E Delzell, H-P Gelbke, J E Kester, M M Moore, R Waites, S S Sarang
Evaluation of potential health effects associated with occupational and environmental exposure to styrene - an update. Journal of toxicology and environmental health. Part B, Critical reviews 22 (1-4) (2019)